Cornerstone Therapeutics, Oscient deal

On July 13, Oscient filed Chapter 11 Bankruptcy and said it plans to sell to Cornerstone its assets related to Factive gemifloxacin mesylate. Oscient will receive

Read the full 262 word article

How to gain access

Continue reading with a
two-week free trial.